Navigating Treatment Decisions

This article focuses on treatment for clear cell disease, but some of these treatments are also appropriate for patients with non-clear cell disease. Some patients may have only a single metastatic tumor that can be removed by surgery. But most patients with metastatic disease have tumors in many parts of the body. In order to treat all of these tumors, patients are given systemic therapies, which are drugs that travel through the bloodstream and can directly reach cells throughout the body. Immunotherapy is a type of treatment that gives a boost to the immune system. The goal of immunotherapy is to help the patient’s immune system attack the cancer cells. Immunotherapy treatments have been available for decades and have generated renewed interest for treating metastatic RCC patients. Two types of immunotherapy may be used for treating patients with metastatic RCC: interleukin-2 (IL-2), which is given intravenously, and interferon (IFN), which is injected under the skin.1 Several systemic therapies available for RCC patients are called “anti-angiogenic” drugs. During angiogenesis, tumors create blood vessels inside the tumor. These blood vessels supply nutrients and help the tumor to grow. Anti-angiogenic drugs can help to reduce the growth of tumor blood vessels, which in turn can make the tumor stop growing or shrink. Anti-angiogenic drugs that are used for treating RCC include sunitinib, pazopanib, sorafenib, and axitinib.1 All of these drugs come i...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

Publication date: Available online 19 June 2019Source: Biosensors and BioelectronicsAuthor(s): Sattar Akbari Nakhjavani, Hadi Afsharan, Balal Khalilzadeh, Mohammad Hossein Ghahremani, Sandro Carrara, Yadollah OmidiAbstractCarcinoembryonic antigen (CEA) is an important oncomarker for the detection of breast cancer. For ultra-sensitive sensing of CEA with great specificity and accuracy, an innovative and reliable electrochemical immunosensor was developed using various nano-hybrids. A glassy carbon electrode (GC) was modified with thiolated graphene oxide (T-GO) to elevate the active surface area of the electrode. The strept...
Source: Biosensors and Bioelectronics - Category: Biotechnology Source Type: research
Conclusions: Routine coagulation indices can predict nasopharygeal carcinoma, with the combination of prothrombin time, APTT and PDW being strongest. The combination of APTT, fibrinogen and FDPs provides a useful score to predict metastases. These indices should be considered in the diagnosis and staging of this disease. PMID: 31210089 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
ConclusionAvailable data suggest that the information needs of people with low back pain are centred around their desire for a diagnosis, potentially contributing to expectations for and overuse of imaging. People with low back pain expressed a strong desire for clear, consistent and personalised information on prognosis, treatment options and self-management strategies, related to healthcare and occupational issues. To correct unhelpful beliefs and optimise delivery of evidence-based therapy, patient and healthcare professional education (potentially by an integrated public health approach) may be warranted.
Source: Journal of Physiotherapy - Category: Physiotherapy Source Type: research
for Advanced-stage Kidney Cancer Mayer N. Fishman, MD, PhD For the patient with advanced-stage kidney cancer, deciding on a course of treatment presents diverse choices. The physician must weigh how quickly the cancer is spreading, the pattern of that spread, and relative risks from other medical conditions against the patient’s individual treatment goals and medical needs. In many cases of patients with advanced disease, there are therapies that can realistically be used to meet the goals of longer survival, longer time to disease progression, and tumor shrinkage. While choosing a kidney cancer treatment can be a...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
Conclusions VHL/PBRM1 mutations confirmed 3rd subtype identified and under review but appears to be mis-classified tumors.  Shows value of molecular methods rather than new mechanistic insights. Integration with survival outcome—suggests molecular detailing can be prognostic Full integrative analysis in process Preliminary data can be found at FoxO Transcription Factors in mTORC1- Activated Renal Tumorigenesis:  Implications for the RCC Treatment Boyi Gan, MD Anderson Cancer Center FoxO Family Transcription Factors:  mammals possess FoxO...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Anemia | Avastin | Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Clinical Trials | Hospital Management | Hospitals | Hypertension | Immunotherapy | Kidney Cancer | Men | Nutrition | Oral Cancer | Pain | Radiation Therapy | Renal Cell Carcinoma | Skin | Study | Urology & Nephrology | Vaccines | Websites